Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy

Joo, Kowoon; Kwon, Seong Ryul; Lim, Mie Jin; Jung, Kyong-Hee; Joo, Hoyeon; Park, Won

doi:10.3346/jkms.2014.29.5.657

Cited by 23 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in participants with a history of gout and CVE at baseline an increase of 0.1 mmol/L in UA was independently associated with a more than two-fold increase in risk of cardiovascular mortality. This is in line with several studies showing that gout is a more reliable predictor for CVE and associated mortality than hyperuricemia [11, 21, 22, 31, 41, 45, 47, 48]. …”

Section: Discussionsupporting

confidence: 91%

Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study

Nossent

Raymond

Divitini

et al. 2016

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundTo investigate the impact of uric acid (UA) levels on cardiovascular disease and mortality at a population level.MethodsProspective analysis of baseline serum UA measurement and 15 year follow-up data from the Busselton Health Survey (n = 4,173), stratified by existence or absence of baseline cardiovascular disease. Outcomes were ascertained from state-wide hospital discharge and mortality registries. Cox regression produced adjusted hazard ratios (HR) for UA level as continuous and categorical (low, medium, high) predictor for cardiovascular events (CVE) and mortality. Gout was defined as a patient’s self-reported history of gout.ResultsAfter age and gender adjustment each 0.1 mmol/L rise in UA level was associated with increased mortality (HR 1.19, CI 1.04–1.36), cardiovascular mortality (HR 1.27, CI 1.03–1.57) and first CVE (HR 1.28, CI 1.13–1.44) in participants with no history of CVE. Adjustment for behavioural and biomedical risk factors of cardiovascular disease attenuated these associations. Results for participants with a history of CVE and for a subset of 1,632 participants using UA levels (2–6 measurements) averaged over time were similar. The overall prevalence of hyperuricemia was 10.7%. When stratified by history of gout, UA level was significantly associated with increased risk of cardiovascular mortality only in participants with a history of CVE (HR 2.13, CI 1.03–4.43).ConclusionsDespite the considerable prevalence of hyperuricemia in 10.7% of the population, single or time averaged measures of UA were not independently predictive of incident cardiovascular disease or mortality. Hyperuricemia did associate with an increased risk of cardiovascular death only in participants with gout and existing cardiovascular disease.Electronic supplementary materialThe online version of this article (doi:10.1186/s12872-016-0421-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 91%

Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study

Nossent

Raymond

Divitini

et al. 2016

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…An interesting retrospective study conducted on 200 Korean patients with a mean follow-up of 7.6 years showed a significant reduction in incident hypertension, type II diabetes and cardiovascular disease in patients with hyperuricemia with deposition that had been properly treated to a cut-off value of 6 mg/dl [109].…”

Section: Important Questionsmentioning

confidence: 99%

Serum uric acid and the risk of cardiovascular and renal disease

Borghi

Rosei

Bardin³

et al. 2015

Journal of Hypertension

427

277

View full text Add to dashboard Cite

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

show abstract

“…In fact, among seven common chronic diseases, patients with gout had the poorest adherence, with only 36.8% participants achieving adherence, and a considerable 24.2% participants demonstrated poor adherence (Briesacher, Andrade, Fouayzi, & Chan, ). Inadequately controlled serum urate levels due to suboptimal adherence to ULT in the long‐term leads to an increased frequency of gout flare (Joo et al., ) and higher gout‐related healthcare use and cost (Halpern et al., ; Park, Rascati, Prasla, & McBayne, ). To better manage gout, patients need to be aware of the importance of adherence to ULT (Bardin & Desideri, ).…”

Section: Introductionmentioning

confidence: 99%

Factors influencing medication adherence in patients with gout: A descriptive correlational study

Chua

Lim

et al. 2017

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy

Cited by 23 publications

References 30 publications

Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study

Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study

Serum uric acid and the risk of cardiovascular and renal disease

Factors influencing medication adherence in patients with gout: A descriptive correlational study

Contact Info

Product

Resources

About